Project Grant R01HL178979
Award Date
5/1/25
Completion Date
2/28/29
Dollars Obligated
$693K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
The federal Project Grant award R21HL172497, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program, supports the engineering of a lab-on-a-particle platform to measure platelet function. The $225,600 award to the University of Colorado-Denver aims to design elastic hydrogel microparticles that can assess platelet adhesion, activation, aggregation, and contraction through high-throughput kinetic and equilibrium assays....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $718,986 Cooperative Agreement to Emory University on May 15, 2024 under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The funding supports the "1/2 Neonatal Platelet Transfusion Threshold Trial (NEOPLATT)" project, which focuses on understanding and improving platelet transfusion practices for extremely preterm infants born at 23 to 26 weeks gestation. This population has the highest risk of...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $144,362 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Baylor College of Medicine. The grant aims to develop a novel optical coherence tomography (OCT) method for volumetric, dynamic, and quantitative analysis of blood flow in the early mouse embryonic cardiovascular system. The research will combine live mouse embryo dissection and culture, optimize a custom OCT imaging protocol, and develop...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $344,304 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Trustees of Boston University, doing business as Boston University Medical Campus. The grant will fund a research project titled "A Learning Health System Approach to Improve the Effectiveness of Blood Transfusions During Septic Shock" over a period from August 15, 2024 to July 31, 2029. The project aims to investigate treatment...
The U.S. National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), awarded a $6,937,947 Cooperative Agreement to the Research Triangle Institute (RTI International) to conduct the "Neonatal Platelet Transfusion Threshold Trial (NEOPLATT)." This 7-year project aims to study optimal platelet transfusion thresholds for extremely preterm infants to reduce the risk of severe intracranial hemorrhage, which is a...
The National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded a $295,963 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to New Health Sciences, Inc. (d/b/a Hemanext Inc.) to evaluate the hemostatic function of platelets stored under hypoxic conditions. The goal is to develop a modernized whole blood storage platform that reduces initial oxygen content and maintains an oxygen-managed environment during refrigerated storage....
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $265,347 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Functional Fluidics Inc., a minority-owned for-profit company in Detroit, Michigan. The goal of this Phase I grant is to develop and initially validate a microfluidic-based Dynamic Sickling Assay (DSA) as a point-of-care device to assess red blood cell sickling and monitor treatment progress in sickle cell disease patients. The proposed DSA...
This $568,264 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the development of a scalable bioprocess for manufacturing human red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The primary goal is to produce designer RBCs with unique antigen profiles that can be used as reagents to identify complex antibodies in patients requiring blood transfusions, particularly...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 to Bloodworks (formerly Puget Sound Blood Center and Program) to conduct molecular and translational research on the mechanisms of disease in von Willebrand disease and sickle cell disease. The research aims to increase understanding of these blood disorders, identify new biomarkers, and explore potential new...
The National Heart, Lung, and Blood Institute (NHLBI) has awarded a $483,852 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a high-throughput platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to enable the optimization of emerging sickle cell disease...